This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PARG / Poly(ADP-ribose) glycohydrolase · Western blot design guide
Design a Western Blot for PARG
Real validated PARG Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-PARG WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
PARG Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~111.1 kDa | |
| Observed band | ~130 kDa | |
| Gel | 8% (catalog A04301-1) | |
| Positive control | Breast (IHC candidate; verify WB) +4 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Acetylated | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 5 isoform(s) |
Section 1
Real Curated PARG Western Blot Protocols
The A04301-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human K562, human Hela, human A549 (catalog A04301-1) |
| Gel % | 8% (catalog A04301-1) |
| Load | 30 ug; reducing conditions (catalog A04301-1) |
| Transfer | a nitrocellulose membrane at 150 mA for 50-90 minutes (catalog A04301-1) |
| Membrane | nitrocellulose membrane (catalog A04301-1) |
| Blocking | 5% non-fat milk/TBS for 1.5 hour at RT (catalog A04301-1) |
| Primary antibody | A04301-1 · 0.5 μg/mL (catalog A04301-1) |
| Primary incubation | overnight at 4°C (catalog A04301-1) |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 (catalog A04301-1) |
| Secondary incubation | 1.5 hour at RT (catalog A04301-1) |
| Wash | TBS-0.1%Tween 3 times with 5 minutes each (catalog A04301-1) |
| Detection | ECL (catalog A04301-1) |
Section 2
What Is the Expected PARG Western Blot Band Size?
PARG is predicted at 111.1 kDa, but its observed band is near 130 kDa; the cause of the difference is not established.
| Band near 130 kDa | Empirical PARG band in reducing whole-cell lysates; confirm identity with a specificity control |
| Band near 111 kDa | Near the sequence-based predicted mass; identity requires confirmation |
| Several bands at different positions | Five named isoforms could contribute, but distinct migration is unproven |
| Weak band in a cytoplasmic fraction | Isoform 1 is nuclear and can relocalize to the cytoplasm after DNA damage |
💡Expected PARG appearancePARG is predicted at 111.1 kDa, while antibody QC detected a band near 130 kDa in reducing whole-cell lysates; the difference is unexplained, so confirm band identity with a specificity control.
| Predicted molecular mass | The supplied sequence predicts 111.1 kDa; the observed band is near 130 kDa |
| Isoform 1 | Its individual apparent mass is not supplied |
| Isoforms 2 and 3 | Alternative splicing may alter size, but individual masses and migration are not supplied |
| Isoforms 4 and 5 | Alternative splicing may alter size, but individual masses and migration are not supplied |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | The observed PARG band is near 130 kDa rather than the predicted 111.1 kDa; the cause is not established | Compare with the QC blot and confirm identity by PARG depletion |
| Band lower than expected | An isoform is possible, but its mass is not supplied | Check which isoforms the antibody recognizes and confirm the band by PARG depletion |
| Multiple bands | Five isoforms are named, but distinct bands are not demonstrated | Compare isoform expression and test band specificity by PARG depletion |
| Weak or no signal | Isoform 1 is nuclear and may be underrepresented in a cytoplasmic fraction | Check a nuclear fraction and verify extraction and antibody performance |
| Fragments below expected size | Sample degradation is possible; no cleavage product is specified | Prepare fresh samples with protease inhibitors and confirm PARG specificity |
Experiment evidence
Western blot images showing PARG band
A04301-1 · PARG
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for PARG Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for PARG in Western blot, you can use breast tissue, which HPA scores High.
Positive control: Breast (IHC candidate; verify WB)
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: HPA lists adipose tissue as not detected, and nuclear enrichment may help detect nuclear PARG isoform 1.
HPA tissue expression evidence for PARG
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | glandular cells | High | Protein (IHC) | HPA → |
| Cervix | squamous epithelial cells | High | Protein (IHC) | HPA → |
| Esophagus | squamous epithelial cells | High | Protein (IHC) | HPA → |
| Fallopian tube | ciliated cells (ciliary rootlets) | High | Protein (IHC) | HPA → |
| Gallbladder | glandular cells | High | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Lung | alveolar cells | Not detected | Protein (IHC) | HPA → |
| Lymph node | germinal center cells | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Soft tissue | fibroblasts | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced PARG Western Blot Tips
Deeper troubleshooting and optimisation questions for PARG, answered from its protein features.
How should PARG band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Which PARG isoforms could produce different bands?
Isoforms · Five isoforms are listed. Relative to the canonical sequence, isoform 2 lacks residues 1–82, isoform 3 lacks 1–108, and isoform 5 lacks 1–460. Isoform 4 replaces residues 1–15 and lacks 16–423; isoforms 4 and 5 also alter 485–526. Check whether the antibody recognizes sequence retained in the isoform you intend to detect. These sequence differences do not establish exact band positions.
Which phosphorylation sites are annotated for PARG?
PTM · The supplied UniProt annotations list phosphoserine at 22, 68, 133, 137, 197, 261, 264, 286, 291, 298, 302, 316, and 448, plus phosphothreonine at 139 and 199. These are UniProt coordinates; antibody or paper numbering may differ. The annotations alone do not predict a visible shift.
UniProt lists N6-acetyllysine at position 340. The supplied position 448 entry reads 'Phosphoserine N-acetylmethionine'; retain that annotation as written rather than assigning it a different residue or coordinate. These are UniProt coordinates and may differ from antibody or paper numbering. Neither entry establishes a distinct Western blot band.
UniProt lists N6-acetyllysine at position 340. The supplied position 448 entry reads 'Phosphoserine N-acetylmethionine'; retain that annotation as written rather than assigning it a different residue or coordinate. These are UniProt coordinates and may differ from antibody or paper numbering. Neither entry establishes a distinct Western blot band.
Does this guide establish induction of PARG?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for PARG?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A04301-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How can PARG be quantified across nuclear and cytoplasmic fractions?
Quantitation · Quantify each fraction consistently and identify which band is being measured. Isoform 1 is nuclear and can relocalize to the cytoplasm after DNA damage, so a change in one fraction need not mean a change in total PARG. The supplied features do not establish a preferred normalization method.
Why might PARG appear near 130 kDa instead of 111.1 kDa?
Interpretation · The supplied blot observation is ~130 kDa; the predicted mass is 111.1 kDa. The listed features do not establish the cause of this difference. Compare the band with a molecular weight marker and report its apparent mass separately from the prediction.
The supplied location feature says isoform 1 relocalizes from the nucleus to the cytoplasm in response to DNA damage. When comparing nuclear or cytoplasmic fractions, record DNA damage conditions and interpret changes in each fraction alongside this relocation. The feature does not establish an increase in total PARG abundance.
Check apparent size and whether the antibody's target sequence is retained in the five listed isoforms. Their documented sequence differences make multiple sizes plausible, but the features do not identify any particular unexpected band. The annotated modifications likewise do not prove that a separate band is modification dependent.
The supplied location feature says isoform 1 relocalizes from the nucleus to the cytoplasm in response to DNA damage. When comparing nuclear or cytoplasmic fractions, record DNA damage conditions and interpret changes in each fraction alongside this relocation. The feature does not establish an increase in total PARG abundance.
Check apparent size and whether the antibody's target sequence is retained in the five listed isoforms. Their documented sequence differences make multiple sizes plausible, but the features do not identify any particular unexpected band. The annotated modifications likewise do not prove that a separate band is modification dependent.
Boster reagents
PARG Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-PARG Antibody Picoband®
Cat # A04301-1
A04301-1 is a human-reactive anti-PARG antibody with a Western blot image from K562, HeLa, and A549 whole-cell lysates. The caption reports a band near 130 kDa versus an expected 111 kDa; no independent identity confirmation is supplied.
Which to pick: A04301-1 is the only listed option. Choose it for a human PARG Western blot when the reported lysate examples are relevant, and account for the observed 130 kDa band when interpreting results.
Source: BosterBio PARG gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q86W56.
- Human Protein Atlas. PARG tissue expression.
- PMC3698538 — target-verified WB comparison
- PMC4929728 — target-verified WB comparison
- PMC8182744 — target-verified WB comparison